Esperion Therapeutics, Inc. Exhibit
EX-99.1 2 a18-38164_1ex99d1.htm EX-99.1 Exhibit 99.1     Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid   — Study Met Safety and Tolerability Endpoints in 52-Week Study — — Bempedoic Acid Achieved Additional 18% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% hsCRP Reduction — — 5-Component MACE Events in the Bempedoic Acid Arm were 6.1% as Compared to 8.2% for Placebo — — Reduction in HbA1c of 0.21% in Patients with Diabetes — — Conference Call and Webcast on Monday,…
To view the full exhibit click here

About Esperion Therapeutics,Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.